NOTICE OF MAILING CHANGE
☐ Check here if you wish to discontinue receiving this publication
☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide
Distribution Center
National Institutes of Health
Room B4B-N-08, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
OFFICIAL BUSINESS
Penalty for Private Use, $300

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 17, No. 22
July 1, 1988
NOTICES

AVAILABILITY OF RETINAL DEGENERATION MUTANTS .................................................. 1
National Eye Institute
Index: EYE

THE ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION
ESTABLISHES THE ADAMHA REVIEWERS RESERVE ........................................... 3
Alcohol, Drug Abuse, and Mental Health Administration
Index: ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

PRIMARY RODENT PRODUCTION CENTERS (RFP) .................................................... 3
National Cancer Institute
Index: CANCER

MICROSTIMULATION OF THE SACRAL SPINAL CORD (RFP) ........................................ 4
National Institute of Neurological and Communicative Disorders and Stroke
Index: NEUROLOGICAL AND COMMUNICATIVE DISORDERS AND STROKE

REVERSIBLE CONTRACEPTION AND RISK OF HIV INFECTION IN WOMEN (RFP) .......... 4
National Institute of Child Health and Human Development
Index: CHILD HEALTH AND HUMAN DEVELOPMENT

LIVER TRANSPLANTATION COORDINATING CENTER (RFP) .......................................... 5
National Institute of Diabetes, and Digestive and Kidney Diseases
Index: DIABETES, DIGESTIVE AND KIDNEY DISEASES

LIVER TRANSPLANTATION CENTERS (RFP) .............................................................. 5
National Institute of Diabetes, and Digestive and Kidney Diseases
Index: DIABETES, DIGESTIVE AND KIDNEY DISEASES

CHARACTERIZATION OF THE GENOMES OF HUMANS AND MODEL ORGANISMS (RFA) ................................................................. 6
National Institute of General Medical Sciences
Index: GENERAL MEDICAL SCIENCES

NEW TECHNOLOGY FOR GENOMIC ANALYSIS (RFA) .................................................. 7
National Institute of General Medical Sciences
Index: GENERAL MEDICAL SCIENCES
NOTICES

AVAILABILITY OF RETINAL DEGENERATION MUTANTS

P.T. 34; K.W. 0715100, 0780005, 1002002

National Eye Institute

The National Eye Institute (NEI) supports the breeding and the distribution of well-characterized retinal degeneration mutants to qualified investigators. Mutants (mice, rats, and dogs) and some limited services (e.g., tissue preparation) are provided. There will be no fee for animals, tissues, or services, but all shipping charges must be met by the investigator. The NEI program goal is to accelerate the pace of research on Retinitis Pigmentosa and other retinal degenerative disorders and to attract new investigators to the field. Some specifics and the name of the appropriate person to contact for complete information follow. NOTE: Guide format restrictions preclude the use of superscript symbols; genetic superscript symbols are printed on the same line as regular text, but are preceded by an asterisk (*).

MICE

Inbred lines of mice with inherited retinal degenerations or other visual system defects are available from two sources, the Division of Neuroscience, Children's Hospital (Boston) and Erasmus University (Rotterdam).

MICE (BOSTON COLONY)

The following table lists the mutant strains that are already established and those that will become available shortly. Additional hypopigmentation mutants and alleles will be added if a demand for them is expressed.

<table>
<thead>
<tr>
<th>Name</th>
<th>Symbol</th>
<th>Strain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Available mutant strains:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albino</td>
<td>c×2J</td>
<td>C57BL/6J-c×2J</td>
</tr>
<tr>
<td>Nervous</td>
<td>nr</td>
<td>BALB/cByJ-nr</td>
</tr>
<tr>
<td>Pearl</td>
<td>pe</td>
<td>C57BL/6J-pe</td>
</tr>
<tr>
<td></td>
<td>pe×H</td>
<td>C57BL/6JPin-pe×H</td>
</tr>
<tr>
<td>Pearl (wild type-revert.)</td>
<td>pe×+Pin</td>
<td>C57BL/6JPin-pe×+Pin</td>
</tr>
<tr>
<td>Pink-eyed unstable</td>
<td>p×un</td>
<td>C57BL/6J-p×un</td>
</tr>
<tr>
<td>Purkinje cell degeneration</td>
<td>pcd</td>
<td>BALB/cByJ-pcd</td>
</tr>
<tr>
<td>Retinal degeneration</td>
<td>rd</td>
<td>C3H/HeJ</td>
</tr>
<tr>
<td>Ruby-eye-2</td>
<td>ru-2×J</td>
<td>C57BL/6J-ru-2×J</td>
</tr>
<tr>
<td>Flecked</td>
<td>T(X;7)1Ct</td>
<td>Dp/X c×2J/Df</td>
</tr>
<tr>
<td>(Cattanach's translocation)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional strains to be made available at a later date:

<table>
<thead>
<tr>
<th>Name</th>
<th>Symbol</th>
<th>Strain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purkinje cell degeneration</td>
<td>pcd×2J</td>
<td>SM/J-pcd×2J</td>
</tr>
<tr>
<td>Purkinje cell degeneration</td>
<td>pcd×Sld</td>
<td>C57BL/6J-pcd×Sld</td>
</tr>
<tr>
<td>Steel Dickie</td>
<td>Sl×d</td>
<td>C57BL/6J</td>
</tr>
<tr>
<td>Vitiligo</td>
<td>vit</td>
<td>C57BL/6J-vit</td>
</tr>
</tbody>
</table>

For further information, contact:

Dr. Richard L. Sidman or Dr. Paul Neumann
Division of Neuroscience
Children's Hospital
300 Longwood Avenue
Boston, Massachusetts 02115
Telephone: (617) 735-6077 or -6076

MICE (ROTTERDAM COLONY)

Retinal degeneration (rd) and Retinal degeneration slow, (rds) are available separately and as a double mutant on the pigmented C3H-rd×+ and albino BALB/c congenic lines.

For further information contact:

Vol. 17, No. 22, July 1, 1988 - Page 1
RATS

Royal College of Surgeons (RCS) rats with inherited retinal dystrophy and several congenic strains of RCS animals are available as follows:

<table>
<thead>
<tr>
<th>RCS</th>
<th>Pink-eyed dystrophic strain</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCS-rdy††</td>
<td>Pink-eyed normal (control) strain</td>
</tr>
<tr>
<td>RCS-p‡‡</td>
<td>Black-eyed dystrophic strain</td>
</tr>
<tr>
<td>RCS-rdy‡‡p‡‡</td>
<td>Black-eyed normal (control) strain</td>
</tr>
<tr>
<td>RCS-c</td>
<td>Albino dystrophic strain</td>
</tr>
</tbody>
</table>

(Available as non-congenic stock 1988, congenic stock, 1990)

Congenic F344-c/+ rats are also available. This strain provides genetically similar albino and hooded (black pigmented) littermate animals with normal retinas. These animals are optimal for the study of pigmentation differences in such research areas as light-induced retinal degeneration or ganglion cell axonal guidance mechanisms.

For further information, contact:

Dr. Matthew M. LaVail or Ms. Nancy Lawson
University of California, San Francisco
Department of Anatomy, Box 0452
San Francisco, California 94143
Telephone: (415) 476-4234

DOGS

Animals and tissues are available on a competitive basis. A brief research protocol will be requested and reviewed for scientific merit by an independent advisory committee. Approved investigators may elect to have dogs shipped to their institution or to have ocular and/or nonocular tissues collected and shipped from the colony following agreement on preservation and shipping protocols.

Miniature poodles either affected with, heterozygous for, or homozygous normal for progressive rod cone degeneration (prcd). The retinal degeneration in prcd-affected m. poodles is a late onset disorder characterized by an abnormally low rod outer segment (ROS) renewal rate.

Irish setters either affected with, heterozygous for, or homozygous normal for rod cone dysplasia (rcdl). The retinal degeneration in rcdl-affected Irish setters is an early onset disorder characterized by arrested development of ROS and abnormal retinal cyclic GMP metabolism.

Norwegian elkhounds either affected with or heterozygous for early retinal degeneration (erd). The colony is composed of crossbred elkhound-beagles, derived from the original purebred Norwegian elkhounds in which the disease erd was first recognized. The retinal degeneration in erd-affected dogs is an early onset disorder characterized by abnormal development of rod inner and outer segments and of rod and cone synaptic terminals. Retinal cyclic GMP metabolism is normal.

For further information, contact:

Dr. Anita A. Suran
National Eye Institute
National Institutes of Health
Building 31, Room 6A49
Bethesda, Maryland 20892
Telephone: (301) 496-5983
The Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) is establishing the ADAMHA Reviewers Reserve (ARR), which will become operational in July. ARR members will be able to participate in the same manner as fully appointed members in meetings of ADAMHA's chartered initial review groups (IRGs) that evaluate grant and cooperative agreement applications and research and development contract proposals. The Office of Extramural Programs, Office of the Administrator, ADAMHA, will manage the Reserve for agency-wide use. Nominations to the Reserve will be made by the three ADAMHA Institutes, primarily from among the pool of retiring members of chartered IRGs. On behalf of the Administrator, ADAMHA, the Institute Directors will select, invite, and appoint highly qualified scientists and other technical experts to serve on the Reserve. Appointment to the Reserve may be for up to four years as long as members file and maintain a current Form HHS 474 (Statement of Employment and Financial Interests) and do not accept appointment to any chartered Department of Health and Human Services public advisory committee. At the request of an Executive Secretary, Reserve members may participate with up to two chartered IRGs during any one grant review cycle; however, they may not serve on the same IRG more than twice in one year. The number of Reserve members that may participate in this capacity at a given chartered IRG meeting is limited to no more than half of the committee's quorum. As in the past, Executive Secretaries may also invite ad hoc special reviewers to provide advice and counsel to chartered IRGs. However, ad hoc special reviewers do not have the rights, privileges, nor obligations of appointed IRG or Reserve members and may not offer or vote on motions nor assign priority ratings. The roster of reviewers provided as part of the summary statement (pink sheet) will list and specify appointed IRG and ARR members and ad hoc consultants.

DATED ANNOUNCEMENTS (RFPs AND RFAs AVAILABLE)

PRIMARY RODENT PRODUCTION CENTERS

RFP AVAILABLE: NCI-CM-97575-72

P.T. 34; K.W. 1002002

National Cancer Institute

The Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI), National Institutes of Health (NIH), is seeking organizations with the capabilities and facilities for producing large numbers of inbred rodents which are genetically sound and free of pathogenic organisms. To be considered for contract award, offerors should meet the following criteria: (1) the principal investigator and other key personnel must have experience and expertise in the production of the highest quality rodents free from pathogenic organisms; (2) the facility must be available at the time of contract award, capable of producing highest quality rodents at task levels; (3) organizational experience in pertinent areas of quality rodent production including pedigrees procedures, isolator production, etc., at a scale commensurate with task performance; and (4) willingness to participate in grantees reimbursement collections. It is anticipated that three (3) awards will be made at the various task levels. Only one (1) award will be made to any organization.

All interested organizations may submit written requests for copies of the Request for Proposals (RFP) NCI CM 97575-72. For our convenience, please enclose two return labels with all requests. The RFP is scheduled to be available on or about June 27, 1988, with a deadline for receipt of proposals on or about August 15, 1988. All responsible offerors may submit proposals for consideration by the National Cancer Institute. For further information regarding this solicitation please direct all correspondence to:

Ms. Jacqueline Ballard
Contract Specialist
Treatment Contracts Section
Research Contracts Branch
National Cancer Institute
Blair Building, Rm. 224
Bethesda, Maryland 20892
MICROSTIMULATION OF THE SACRAL SPINAL CORD

RFP AVAILABLE: NIH-NINCDS-88-15

P.T. 34; K.W. 0740050

National Institute of Neurological and Communicative Disorders and Stroke

The National Institute of Neurological and Communicative Disorders and Stroke has a requirement to investigate the feasibility of microstimulation of the sacral spinal cord as a method of controlling micturition and sexual functions.

Offerors should have experience in electrophysiology including electrical stimulation of neural tissue.

This is an announcement of an anticipated Request for Proposals. RFP-NIH-NINCDS-88-15 will be issued on or about August 1, 1988, with a closing date for receipt of proposals set for September 30, 1988.

To receive a copy of the RFP, please supply this office with two self-addressed mailing labels. All responsible sources may submit a proposal which will be considered by the agency. The RFP will be available upon written request to:

Contracting Officer
Contracts Management Branch, NINCDS
National Institutes of Health
Federal Building, Room 901
Bethesda, Maryland 20892

REVERSIBLE CONTRACEPTION AND RISK OF HIV INFECTION IN WOMEN

RFP AVAILABLE: NICHD-CE-88-12

P.T. 34; K.W. 0750020, 0411005, 0715120

National Institute of Child Health and Human Development

The Contraceptive Evaluation Branch of the Center for Population Research, NICHD, has a requirement for a case-control study of the relationships between reversible contraceptive methods and incident HIV infection in sexually active women of reproductive age with no risk factors for HIV infection other than vaginal intercourse. The objectives of the study are to determine:

1) Relative risk of incident HIV infection in women who are currently using various reversible contraceptive methods when compared to non-contraceptors. Although a full contraceptive history will be obtained, specific attention will be paid to the use of condoms, spermicides and oral contraceptives.

2) The effects of sexually transmitted diseases and pelvic inflammatory disease (PID) on the relative risks determined for (1) above.

The results from this study will provide NICHD with information necessary for preparing guidelines for the use of contraceptive methods in the control of the AIDS epidemic.

This announcement is not a request for proposals (RFP). RFP-NICHD-CE-88-12 will be issued on or about June 30, 1988. Proposals will be due approximately 120 days thereafter. Copies of the RFP may be obtained by sending a written request to the following address. Please enclose a self-addressed label.

Paul J. Duska, Contracting Officer
Contracts Management Section, OGC
National Institute of Child Health and Human Development
Executive Plaza North, Room 610
Bethesda, Maryland 20892
LIVER TRANSPLANTATION COORDINATING CENTER

RFP AVAILABLE: RFP-NIH-NIDDK-88-3
P.T. 34; K.W. 07455015, 1004008

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has a requirement to support a fully operational liver transplantation database for the collection of data from patients in the United States who have been evaluated and have had liver transplantation for a variety of end-stage liver diseases. The overall goal of this Liver Transplantation Database is to answer important research questions about liver transplantation. This project will consist of contracts for approximately 5 Liver Transplantation Centers and one Coordinating Center. This Operational Phase will be subdivided into the following segments: a 3-month transition phase will allow time for any necessary modification of the data collection forms and procedures developed in the developmental and pilot phases; the recruitment segment is planned to last 3 years or until at least 750 patients and no more than 1500 patients who receive liver transplantation have been entered into the database; the follow-up phase will allow for the follow-up of all patients entered into the database for an additional 2 years; and the analysis phase will allow 2 years for the completion of data analysis and the storage of data.

During this operational phase, the Coordinating Center and Transplantation Centers will be involved in applying the methodology developed during the preceding development and pilot phases.

The Coordinating Center will be responsible for monitoring the data collection and recording, editing, storing, and analyzing all of the data, and for maintaining the data collection system used by the Transplantation Centers. The Coordinating Center will work with each Transplantation Center to assure that the data is collected according to standard procedures. It will analyze the data to monitor the progress of the project and to answer research questions about liver transplantation.

This Request for Proposals, RFP No. NIH-NIDDK-88-3, will be issued on or about July 11, 1988, with a closing date set for October 11, 1988.

To receive a copy of this RFP, please supply this office with two self-addressed mailing labels and cite the RFP number referenced above. Requests must be in writing and addressed to:

Shirley A. Shores  
Contracts Management Branch  
National Institute of Diabetes and Digestive and Kidney Diseases  
Westwood Building, Room 602  
Bethesda, Maryland 20892

Telephone requests will not be honored. A reasonable number of the RFP has been prepared and will be issued on an as-available basis. This advertisement does not commit the Government to make an award.

LIVER TRANSPLANTATION CENTERS

RFP AVAILABLE: RFP-NIH-NIDDK-88-4
P.T. 04; K.W. 0745065, 0785035, 0785085

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has a requirement to support a fully operational liver transplantation database for the collection of data from patients in the United States who have been evaluated and have had liver transplantation for a variety of end-stage liver diseases. The overall goal of this Liver Transplantation Database is to answer important research questions about liver transplantation. This project will consist of contracts for approximately 5 Liver Transplantation Centers and one Coordinating Center. This Operational Phase will be subdivided into the following segments: a 3-month transition phase will allow time for any necessary modification of the data collection forms and procedures developed in the developmental and pilot phases; the recruitment segment is planned to last 3 years or until at least 750 patients...
and no more than 1500 patients who receive liver transplantation have been entered into the database; the follow-up phase will allow for the follow-up of all patients entered into the database for an additional 2 years; and the analysis phase will allow 2 years for the completion of data analysis and the storage of data.

During this operational phase, the Coordinating Center and Transplantation Centers will be involved in applying the methodology developed during the preceding development and pilot phases.

The Transplantation Centers will be responsible for patient recruitment and for collecting the required data and submitting it to the Coordinating Center. These Centers will be expected to recruit a sufficient number of patients evaluated for liver transplantation to provide the Liver Transplantation Database with at least one liver transplantation patient a week or at least 50 liver transplantation patients a year. The Transplantation Centers will also be responsible for collecting data on the donor and on the harvesting procedure.

This Request for Proposals, RFP No. NIH-NIDDK-88-4, will be issued on or about July 11, 1988, with a closing date set for October 11, 1988.

To receive a copy of this RFP, please supply this office with two self-addressed mailing labels and cite the RFP number referenced above. Requests must be in writing and addressed to:

Shirley A. Shores
Contracts Management Branch
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 602
Bethesda, Maryland 20892

Telephone requests will not be honored. A reasonable number of the RFP has been prepared and will be issued on an as available basis. This advertisement does not commit the Government to make an award.

CHARACTERIZATION OF THE GENOMES OF HUMANS AND MODEL ORGANISMS

RFA AVAILABLE: 88-GM-02
P.T. 34; K.W. 1002019, 0755045
National Institute of General Medical Sciences
Application Receipt Date: September 22, 1988

BACKGROUND INFORMATION

The National Institute of General Medical Sciences (NIGMS) supports research in the field of genomic analysis, with the goal of developing detailed genetic and physical maps and, eventually, determining the complete sequence of the DNA of a number of organisms, including man. It is expected that this knowledge will ultimately be applied to the prevention, diagnosis, and treatment of human disorders. The objective of this Request for Applications (RFA) is to stimulate innovative research that will rapidly improve our ability to analyze the entire genome of an organism.

RESEARCH GOALS AND SCOPE

The NIGMS invites applications from interested investigators for research which involves the further development of physical maps of the human genome; development of physical maps and/or determination of the DNA sequence of the genome of one of the following model organisms: yeast, Drosophila, mouse or the nematode worm, Caenorhabditis elegans; or development of new approaches for determination of such mapping or sequence information. [Research projects directed toward these goals but which utilize other organisms are appropriately submitted in response to an existing NIH Program Announcement (NIH Guide for Grants and Contracts, Vol. 16, No. 18, p. 11; May 27, 1987)].

To be considered responsive to this RFA, proposals must be primarily directed toward the development of new mapping and sequencing data or the development of new methodological approaches which will increase the accuracy, ease, and rapidity with which such mapping and sequence determination can be achieved. Innovative approaches to obtaining such information are encouraged. Utilization of physical mapping and DNA sequence data for the analysis and
characterization of genomic information is also encouraged as part of the proposed projects. However, applications in which the primary goal is the study of biology of specific genomic regions (particularly regions related to disease genes), and in which mapping or sequence data are to be obtained only as a necessary first step toward that end, will not be considered responsive to this announcement.

MECHANISM OF SUPPORT

Support will be through research grants including individual projects grants (R01, R29) and program projects grants (P01). The total amount of support for grants under this RFA is contingent upon the appropriation of funds for this purpose. The number of awards will be determined by the merit of the proposals, by their relevance to the program goals, and availability of funds. It is anticipated that in Fiscal Year 1989 up to five million dollars will be allocated to the research initiatives described in this RFA, allowing approximately 10-30 awards to be made. This amount may be increased if a large number of highly meritorious applications are received and if funds are available.

STAFF CONTACT

Applicants should request the complete RFA and obtain additional information from:

Dr. Mark Guyer or Dr. Irene Eckstand
National Institute of General Medical Science
Westwood Building, Room 918
National Institute of Health
Bethesda, Maryland 20892
Telephone: (301) 496-7137

NEW TECHNOLOGY FOR GENOMIC ANALYSIS

RFA AVAILABLE: 88-GM-03
P.T. 34; K.W. 1002019, 0755045, 1004000, 0735000
National Institute of General Medical Sciences
Application Receipt Date: December 1, 1988

BACKGROUND INFORMATION

The National Institute of General Medical Science (NIGMS) supports research in basic genetics, including research directed toward the construction of detailed genetic and physical maps of the genomes of a number of organisms, including man, and the determination of the complete sequence of the DNA of those organisms. This knowledge will ultimately be applied in biomedical research for the diagnosis, treatment, and prevention of human disease. Significant advances have been made during the past decade in the techniques available for determination of genomic structure and organization and of nucleic acid sequences. The objective of the Request for Applications (RFA) is to stimulate innovative research that will lead to further improvements in the speed and efficiency of map construction and DNA sequence determination, so that major research efforts such as determining the entire DNA sequence of any organism will become practical in terms of both time and cost.

RESEARCH GOALS AND SCOPE

The NIGMS invites applications from investigators for research that will lead to new or improved technology applicable to genomic analysis. The object of this program is to make substantial improvements in the rapidity, efficiency and accuracy with which genetic mapping, physical mapping, and DNA sequence information can be obtained, analyzed, and distributed. Multi-disciplinary approaches to the attainment of these goals are encouraged; in addition to scientists in all areas of the biological sciences, we encourage the participation of scientists in disciplines which have not previously received major amounts of support from the National Institute of Health (NIH), such as computer science, materials science, physics, mathematics and engineering.

MECHANISM OF SUPPORT

Support will be through research grants including individual projects grants (R01, R29) and program projects grants (P01). The total amount of support for grants under this RFA is contingent upon the appropriation of funds for this purpose. The number of awards will be determined by the merit of the
proposals and by the relevance to the program goals, as well as by availability of funds. It is anticipated that in Fiscal Year 1989 up to five million dollars will be allocated to the research initiatives described in this RFA, allowing approximately 10-30 awards to be made. This amount may be increased if a large number of highly meritorious applications are received and if funds are available.

STAFF CONTACT

Applicants should request the complete RFA and obtain additional information from:

Dr. Mark Guyer or Dr. Irene Eckstrand  
National Institute of General Medical Sciences  
Westwood Building, Room 918  
National Institutes of Health  
Bethesda, Maryland 20892  
Telephone: (301) 496-7137